Enliven Therapeutics Inc

NASDAQ:ELVNUnited States

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Enliven Therapeutics, Inc. Selected Condensed Consolidated Financial Information (in thousands, except per share data) (unaudited) Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, ------------------------------------------------ ------------------------------------------------ 2024 2023 2024 2023 ----------------------- ----------------------- ----------------------- ----------------------- Operating expenses: Research and development $ 21,258 $ 19,606 $ 60,054 $ 46,669 General and administrative 5,810 4,642 17,604 14,131 Total operating expenses 27,068 24,248 77,658 60,800 ----------------------- ----------------------- ----------------------- ----------------------- Loss from operations (27,068) (24,248) (77,658) (60,800) Other income (expense), net 3,912 3,479 11,814 8,586 Net loss $ (23,156) $ (20,769) $ (65,844) $ (52,214) ======================= ======================= ======================= ======================= Net loss per share, basic and diluted $ (0.48) $ (0.51) $ (1.43) $ (1.55) Weighted-average shares outstanding, basic and diluted 48,267 41,031 46,137 33,665 Balance Sheets September 30, December 31, 2024 2023 ----------------------- ----------------------- Assets Current assets: Cash, cash equivalents and marketable securities $ 291,834 $ 253,148 Restricted cash 54 54 Prepaid expenses and other current assets 5,109 2,949 Contingent value right asset -- 10,000 ----------------------- ----------------------- Total current assets 296,997 266,151 Property and equipment, net 549 742 Operating lease right-of-use assets 81 320 Deferred offering costs 563 563 Other long-term assets 7,240 4,091 Total assets $ 305,430 $ 271,867 ======================= ======================= Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,019 $ 532 Accrued expenses and other current liabilities 16,008 15,362 Contingent value right liability -- 10,000 ----------------------- ----------------------- Total current liabilities 17,027 25,894 Long-term liabilities -- 67 ----------------------- ----------------------- Total liabilities 17,027 25,961 ----------------------- ----------------------- Stockholders' equity 288,403 245,906 Total liabilities and stockholders' equity $ 305,430 $ 271,867 ======================= =======================